Adenosine diphosphate receptor inhibitor

Adenosine diphosphate (ADP) receptor inhibitor is a class of antiplatelet agents. These drugs inhibit some or all types of adenosine diphosphate receptors (P2Y receptors). P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as ATP, ADP, UTP, UDP and UDP-glucose.

Inhibitors of the receptor subtype P2Y12 are one class of P2Y receptor inhibitors. These drugs include clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor, regrelor,[1] and elinogrel.[2][3][4] These inhibitors prevent expression of glycoproteins IIb/IIIa on the platelet surface.

References

  1. ↑ "Regrelor". pubchem.ncbi.nlm.nih.gov. National Center for Biotechnology Information. Retrieved 3 August 2017.
  2. ↑ Hashemzadeh, M; Goldsberry, S; Furukawa, M; Khoynezhad, A; Movahed, MR (2009). "ADP receptor-blocker thienopyridines: Chemical structures, mode of action and clinical use. A review". The Journal of invasive cardiology. 21 (8): 406–12. PMID 19652255.
  3. ↑ Bauer, Shawn M (2003). "ADP receptor antagonists as antiplatelet therapeutics". Expert Opinion on Emerging Drugs. 8 (1): 93–101. PMID 14610915. doi:10.1517/14728214.8.1.93.
  4. ↑ Michelson, AD (2009). "New P2Y12 antagonists". Current Opinion in Hematology. 16 (5): 371–7. PMID 19550317. doi:10.1097/MOH.0b013e32832ea2f2.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.